News

TechnoPhage announces FDA Fast Track Designation granted to TP-102 for the treatment of patients with infected diabetic foot ulcers.

Phico Therapeutics raises £7 million investment to support SASPject advancement, novel engineered phage technology for next-generation antibiotics to curb antimicrobial resistance (AMR).

The National Institute of Allergy and Infectious Diseases (NIAID), has awarded 12 institutes with grants towards phage therapy research.

Phico Therapeutics receives funding from CARB-X towards the development of engineered bacteriophage with SASP gene targeting Pseudomonas aeruginosa.

BiomX updates on pipeline products against Cystic fibrosis (CF), Atopic dermatitis (AD), Inflammatory bowel disease (IBD), and Primary sclerosing cholangitis (PSC), as well as a treatment against Acne-prone skin and Colorectal cancer.

Cytophage announced the beginning of animal testing of their throat and nasal phage spray that targets the COVID-19 virus.

Skin care products with bacteriophages are currently being developed by several companies dealing with personal care products, in order to address commonly shared skin issues.

TechnoPhage announced the beginning of Phase I/IIa study of TP-102 phage therapy to treat Diabetic Foot Infections (DPI).

Phage therapy for COVID19 patients has been approved by the FDA. Adaptive Phage Therapeutics given a green light to Expanded Access IND to use phage therapy for critical COVID19 patients.

The field of modified bacteriophages has become of great interest, and as of recently gained a lot more attention.